Oral Isotretinoin and Its Uses in Dermatology: A Review
10
Issued Date
2023-01-01
Resource Type
eISSN
11778881
Scopus ID
2-s2.0-85169467649
Pubmed ID
37649956
Journal Title
Drug Design, Development and Therapy
Volume
17
Start Page
2573
End Page
2591
Rights Holder(s)
SCOPUS
Bibliographic Citation
Drug Design, Development and Therapy Vol.17 (2023) , 2573-2591
Suggested Citation
Paichitrojjana A., Paichitrojjana A. Oral Isotretinoin and Its Uses in Dermatology: A Review. Drug Design, Development and Therapy Vol.17 (2023) , 2573-2591. 2591. doi:10.2147/DDDT.S427530 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/89626
Title
Oral Isotretinoin and Its Uses in Dermatology: A Review
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
In 1982, the Food and Drug Administration (FDA) of the United States of America approved isotretinoin (13-cis-retinoic acid), a retinoid derivative of vitamin A, to treat severe recalcitrant acne vulgaris. Apart from its prescribed use for severe acne, evidence suggests that isotretinoin is commonly used off-label to treat mild-to-moderate acne, inflammatory skin conditions, genodermatoses, skin cancer, and other skin disorders. This is due to its anti-inflammatory, immunomodulatory, and antineoplastic properties. Some “off-label” use is successful, while others are ineffective. Therefore, this information is essential to clinicians for deciding on the appropriate use of isotretinoin. In this article, we aim to review the most updated evidence-based data about the use of oral isotretinoin in dermatology.